Ran Frenkel, Chief Development Operations Officer at Karyopharm Therapeutics Inc. (KPTI), sold 1,974 shares at $20.00 ($39K) on 2020-05-07, disclosed to the SEC on 2020-05-11.
Scheduled sale ($39k) by Chief Development Operations Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KPTI | SELL | 2022-02-09 | $20K | — | Filing → |
| KPTI | SELL | 2021-02-22 | $43K | — | Filing → |
| KPTI | SELL | 2021-02-17 | $32K | — | Filing → |